Diligence memo · auto-generated · as of July 2, 2026
Cba Pharma Inc
Cba Pharma Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Cba Pharma Inc operates in Biotechnology, based in LEXINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cba Pharma Inc has raised $10.0M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.3M on 2012-02-13.
Most recent recorded round closed around 2015-01-20.
Valuation (modeled)modeled
Provath models Cba Pharma Inc at approximately $3.6M (range $109K–$20M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.02× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 11.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 5.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 56% of Biotechnology peers (4293 compared).
Modeled value ranks above 8% of those peers.
Closest niche peers: Dnanexus, Inc., Foresight Biotherapeutics, Inc., AuraSense Therapeutics, LLC, Zyomyx Inc, Champions Oncology, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.